Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral propranolol for prevention of threshold retinopathy of prematurity
2017-002124-24Phase 2Active
- Sponsor
- University of Zurich
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of propranolol in retinopathy of prematurity (ROP), sponsored by University of Zurich. Primary endpoint: Prevention of threshold retinopathy of prematurity. Started Sep 2017; status: active.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2017-002124-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002124-24.